MYRIAD GENETICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
MYRIAD GENETICS, INC. (MYGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-07-31
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 0.00 shares.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 0.00 shares.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 0.00 shares.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | 0.00 shares 10-Q · filed 2026-07-31 | 0.00 shares derived: sum of 3 quarters · filed 2026-07-31 | 0.00 shares derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-06 | 0.00 shares derived: sum of 2 quarters · filed 2026-05-06 | 0.00 shares derived: sum of 3 quarters · filed 2026-05-06 | 0.00 shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 0.00 shares derived: sum of 2 quarters · filed 2026-02-24 | 0.00 shares derived: sum of 3 quarters · filed 2026-02-24 | 0.00 shares 10-K · filed 2026-02-24 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-04 | 0.00 shares 10-Q · filed 2025-11-04 | 0.00 shares derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 0.00 shares 10-Q · filed 2025-08-06 | 0.00 shares derived: sum of 3 quarters · filed 2026-02-24 | 0.00 shares derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-07 | 0.00 shares derived: sum of 2 quarters · filed 2026-02-24 | 0.00 shares derived: sum of 3 quarters · filed 2026-02-24 | 0.00 shares derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 0.00 shares derived: sum of 2 quarters · filed 2026-02-24 | 0.00 shares derived: sum of 3 quarters · filed 2026-02-24 | 0.00 shares 10-K · filed 2026-02-24 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-08 | 0.00 shares 10-Q · filed 2024-11-08 | |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 0.00 shares 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | 0.00 shares 10-K · filed 2026-02-24 | |||
| 2022-12-31 | 0.00 shares 10-K · filed 2025-02-28 | |||
| 2021-12-31 | 0.00 shares 10-K · filed 2024-02-28 | |||
| 2020-12-31 | 700.00K shares 10-KT · filed 2021-03-16 | |||
| 2020-06-30 | 0.00 shares 10-K · filed 2023-03-01 | |||
| 2019-06-30 | 0.00 shares 10-K · filed 2022-02-25 | |||
| 2018-06-30 | 0.00 shares 10-KT · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |